Lidocaine Subcutaneous Infusion for Control of Treprostinil Related Site Pain

• Status: Terminated
• Trial end date: 2012-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Treprostinil subcutaneous (under the skin) infusion is a very good medication for treating pulmonary arterial hypertension but infusion site pain may be very severe in some patients. The investigators plan to treat patients receiving treprostinil with a subcutaneous infusion of lidocaine (a local anesthestic) to treat the pain.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jewish General Hospital
• Treatments: Lidocaine; Treprostinil

Criteria

Inclusion Criteria:

• PAH

• Treprostinil treatment for at least 3 months

• Severe infusion site pain

Exclusion Criteria:

• Pregnancy/breastfeeding

• Decompensated heart failure

• Chronic liver disease

• Abnormal electrolytes

• Heart block (2/3 degree), sino-atrial block, idioventricular rhythm

• Systolic systemic BP <90mmHg

• Bradycardia HR <55

• Adverse reaction to lidocaine or other amide local anesthestic

• Interacting medications (anti-arrhythmics, CYP1A2 inhibitors)